Bronchiectasis in Infants and Preschool Children Diagnosed with Cystic Fibrosis after Newborn Screening - 07/08/11
, Siobhain Brennan, BSc (hons), PhD b, Conor Murray, MBBS, Dip Ch, FRANZCR a, Tonia Douglas, MBChB (hons), FRACP a, b, Britta S. von Ungern-Sternberg, MD, DEAA a, Luke W. Garratt, BSc (hons) b, Catherine L. Gangell, BSc (hons), PhD b, Nicholas De Klerk, BSc, MSc, F Ed TC, PhD b, Barry Linnane, MD, PhD d, Sarath Ranganathan, MB ChB, MRCP, PhD, FRCPCH, FRACP d, Phillip Robinson, BMed Sc, MBBS, FRACP, MD, PhD d, Colin Robertson, MBBS, FRACP, MSc (Epi), MD d, Peter D. Sly, MBBS, FRACP, MD, DSci bAustralian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)
Reprint requests: Stephen Stick, Department of Respiratory Medicine, Princess Margaret Hospital for Children, Box D184, Perth 6010, Western Australia.Abstract |
Objectives |
To determine the prevalence of bronchiectasis in young children with cystic fibrosis (CF) diagnosed after newborn screening (NBS) and the relationship of bronchiectasis to pulmonary inflammation and infection.
Study design |
Children were diagnosed with CF after NBS. Computed tomography and bronchoalveolar lavage were performed with anesthesia (n = 96). Scans were analyzed for the presence and extent of abnormalities.
Results |
The prevalence of bronchiectasis was 22% and increased with age (P = .001). Factors associated with bronchiectasis included absolute neutrophil count (P = .03), neutrophil elastase concentration (P = .001), and Pseudomonas aeruginosa infection (P = .03).
Conclusions |
Pulmonary abnormalities are common in infants and young children with CF and relate to neutrophilic inflammation and infection with P. aeruginosa. Current models of care for infants with CF fail to prevent respiratory sequelae. Bronchiectasis is a clinically relevant endpoint that could be used for intervention trials that commence soon after CF is diagnosed after NBS.
Le texte complet de cet article est disponible en PDF.Mots-clés : AREST CF, BAL, BWT, CF, CT, ESP, NBS
Plan
| This study is supported by Cystic Fibrosis Foundation (USA) (Project grant support), National Health and Medical Research Council (Australia) (Project grant support and Fellowships [S.M.S., P.D.S.]), and) Cystic Fibrosis (Australia) (Project grant support). The authors declare no conflicts of interest. |
Vol 155 - N° 5
P. 623 - novembre 2009 Retour au numéro
Article précédent
- A New Cystic Fibrosis Newborn Screening Algorithm: IRT/IRT1↑/DNA
- Marci K. Sontag, Dan Wright, James Beebe, Frank J. Accurso, Scott D. Sagel
- Gastric Acid Inhibition for Fat Malabsorption or Gastroesophageal Reflux Disease in Cystic Fibrosis: Longitudinal Effect on Bacterial Colonization and Pulmonary Function
- Hubert P.J. van der Doef, Hubertus G.M. Arets, Steven P. Froeling, Paul Westers, Roderick H.J. Houwen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?